DexCom (NASDAQ:DXCM – Get Free Report) and Acutus Medical (NASDAQ:AFIB – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Insider & Institutional Ownership
97.8% of DexCom shares are held by institutional investors. Comparatively, 56.9% of Acutus Medical shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 5.2% of Acutus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for DexCom and Acutus Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DexCom | 1 | 3 | 21 | 2 | 2.89 |
| Acutus Medical | 0 | 0 | 0 | 0 | 0.00 |
Risk & Volatility
DexCom has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Acutus Medical has a beta of 5.7, indicating that its share price is 470% more volatile than the S&P 500.
Valuation and Earnings
This table compares DexCom and Acutus Medical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DexCom | $4.66 billion | 7.41 | $836.30 million | $2.53 | 36.18 |
| Acutus Medical | $7.16 million | 0.00 | -$81.66 million | ($0.11) | N/A |
DexCom has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DexCom and Acutus Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DexCom | 20.12% | 35.94% | 14.75% |
| Acutus Medical | -272.74% | -311.64% | -11.57% |
Summary
DexCom beats Acutus Medical on 11 of the 14 factors compared between the two stocks.
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
About Acutus Medical
Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
